APO-ENTECAVIR TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

ENTECAVIR

Saatavilla:

APOTEX INC

ATC-koodi:

J05AF10

INN (Kansainvälinen yleisnimi):

ENTECAVIR

Annos:

0.5MG

Lääkemuoto:

TABLET

Koostumus:

ENTECAVIR 0.5MG

Antoreitti:

ORAL

Kpl paketissa:

30

Prescription tyyppi:

Prescription

Terapeuttinen alue:

NUCLEOSIDES AND NUCLEOTIDES

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0151648001; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2012-11-23

Valmisteyhteenveto

_APO-ENTECAVIR (Entecavir Tablets) _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 52_
PRODUCT MONOGRAPH
PR
APO-ENTECAVIR
Entecavir Tablets
Tablets 0.5 mg
USP
Antiviral
APOTEX INC.
150 Signet Drive
Toronto, Ontario
M9L 1T9
Date of Preparation:
November 23, 2012
Date of Revision:
January 11, 2023
Submission Control Number: 271047
_APO-ENTECAVIR (Entecavir Tablets) _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
3
SUMMARY PRODUCT INFORMATION
.........................................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................................
3
CONTRAINDICATIONS..................................................................................................................
3
WARNINGS AND PRECAUTIONS
..................................................................................................
3
ADVERSE REACTIONS
..................................................................................................................
7
DRUG INTERACTIONS
................................................................................................................
11
DOSAGE AND ADMINISTRATION
...............................................................................................
12
OVERDOSAGE
............................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
.................................................................................
13
STORAGE AND STABILITY
..........................................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................................. 20
PART II: SCIENTIFIC INFORMATION
......................................................................................
22
PHARMAC